Skip to main content
PMC home page
JMIRx Med logoLink to JMIRx Med
. 2021 Sep 27;2(3):e33496. doi: 10.2196/33496

Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

Mark Jarrett 1,✉,#, Warren Licht 1,#, Kevin Bock 1,#, Zenobia Brown 1,#, Jamie Hirsch 1,#, Kevin Coppa 2,#, Rajdeep Brar 1,#, Stephen Bello 2,#, Ira Nash 1,#
Editor: Edward Meinert
PMCID: PMC10414264

This is the authors’ response to peer-review reports for “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study.”

Round 1 Review [1]

  1. Formatting in paper [2] changed as requested

  2. Figures changed

  3. Added suggested contextualization

  4. Fortified Discussion

  5. Although we added references and discussion of the inflammatory response to cytokines, it should be recognized that these antibodies work by neutralization of the virus, not by affecting cytokines.

References

Articles from JMIRx Med are provided here courtesy of JMIR Publications Inc.

RESOURCES